A Phase 1 dose escalation, safety, and pharmacokinetic study of PF-06650808, an anti-Notch3 antibody drug conjugate, in adult patients with advanced solid tumors

被引：4
|
作者：
Rosen, L. S. [1 ]
Wesolowski, R. [2 ]
Gibson, B. [3 ]
Baffa, R. [3 ]
Liao, K. H. [3 ]
Masters, J. [3 ]
Hua, S. Y. [3 ]
Deng, S. [3 ]
Shazer, R. [3 ]
Tolcher, A. W. [4 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Med Ctr,Dept Med 9, Los Angeles, CA 90095 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Breast Canc Res Program, Columbus, OH 43210 USA
[3] Pfizer Inc, Biotechnol Clin Dev, La Jolla, CA USA
[4] South Texas Accelerated Res Therapeut, Clin Res, San Antonio, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31948-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
30LBA
引用
收藏
页码：S725 / S725
页数：1
相关论文
共 50 条
  • [1] A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors
    Lee S. Rosen
    Robert Wesolowski
    Raffaele Baffa
    Kai-Hsin Liao
    Steven Y. Hua
    Brenda L. Gibson
    Steven Pirie-Shepherd
    Anthony W. Tolcher
    Investigational New Drugs, 2020, 38 : 120 - 130
  • [2] A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors
    Rosen, Lee S.
    Wesolowski, Robert
    Baffa, Raffaele
    Liao, Kai-Hsin
    Hua, Steven Y.
    Gibson, Brenda L.
    Pirie-Shepherd, Steven
    Tolcher, Anthony W.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 120 - 130
  • [3] A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
    Gentry T. King
    Keith D. Eaton
    Brandon R. Beagle
    Christopher J. Zopf
    Gilbert Y. Wong
    Heike I. Krupka
    Steven Y. Hua
    Wells A. Messersmith
    Anthony B. El-Khoueiry
    Investigational New Drugs, 2018, 36 : 836 - 847
  • [4] A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
    King, Gentry T.
    Eaton, Keith D.
    Beagle, Brandon R.
    Zopf, Christopher J.
    Wong, Gilbert Y.
    Krupka, Heike I.
    Hua, Steven Y.
    Messersmith, Wells A.
    El-Khoueiry, Anthony B.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 836 - 847
  • [5] Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
    Jang, Sekwon
    Powderly, John D.
    Spira, Alexander I.
    Bakkacha, Ouiam
    Loo, Deryk
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of PF-03732010, an IgG1 monoclonal antibody against P-cadherin (placental), administered to adult patients with advanced solid tumors
    Bang, Y.
    Cohen, R.
    Blumenkopf, T.
    Zhang, Y.
    Toh, M.
    Countouriotis, A.
    Shalinsky, D.
    Zhang, S.
    Gallo, J.
    Desai, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 119 - 119
  • [7] Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
    Meric-Bernstam, Funda
    Calvo, Emiliano
    Lee, Keun Seok
    Moreno, Victor
    Park, Yeon Hee
    Rha, Sun Young
    Chalasani, Pavani
    Zhong, Wei
    Zhou, Li
    Pirie-Shepherd, Steven
    Leung, Abraham C. F.
    Curigliano, Giuseppe
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (10) : 1191 - 1203
  • [8] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [9] Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
    Denlinger, Crystal S.
    Keedy, Vicki L.
    Moyo, Victor
    MacBeath, Gavin
    Shapiro, Geoffrey, I
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1604 - 1612
  • [10] Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
    Crystal S. Denlinger
    Vicki L. Keedy
    Victor Moyo
    Gavin MacBeath
    Geoffrey I. Shapiro
    Investigational New Drugs, 2021, 39 : 1604 - 1612
12345